|
|
|
|
David Largaespada gave a presentation titled "Using Transposons and Targeted Nucleases to Discover Treatment Targets for Cancer" at the University of Utah, Salt Lake City, UT, February 2020.
David Odde presented a seminar to the Department of Biomedical Engineering at Oregon Health Sciences University, Portland, OR, February 2020.
David Odde presented a seminar to the Department of Mechanical and Aerospace Engineering at Oregon Health Sciences University, Portland, OR, February 2020.
Andrew Venteicher presented at the Forbeck Forums: Leveraging Synthetic Lethality to Treat Cancer, San Diego, CA, February 2020.
|
|
David Largaespada has received a grant from Boston Children's Hospital, December 2019, for the project "NF1-related MPNST Patient-Derived Model Program."
Jianfang Ning has received a "Humor to Fight the Tumor" grant from the Humor to Fight the Tumor Foundation, 2020.
David Odde has received an R01 grant from the NIH, 2020, for the project "Investigation of the Role of UNC-45A in Paclitaxel-Mediated Microtubule Stability."
|
|
|
No new clinical trials reported.
|
|
Shamsan GA, Odde DJ. "Emerging Technologies in Mechanotransduction Research." Curr Opin Chem Biol. 2019 Dec;53:125-130. doi: 10.1016/j.cbpa.2019.08.002. PMID: 31618703.
Jules-Dole N, Uribe-Cardenas R, McReynolds LJ, Borden L, Chambers S, Bell WR, Ahn ES, Raabe E, Salpekar JA. "Psychosis Remitted after Ependymoma Resection in a School-Aged Child." J Neuropsychiatry Clin Neurosci. 2019 Dec 4:appineuropsych19070147. doi: 10.1176/appi.neuropsych.19070147. Epub ahead of print. PMID: 31795806.
Horta E, Bongiorno C, Ezzeddine M, Neil EC. "Neurotoxicity of Antibodies in Cancer Therapy: A Review." Clin Neurol Neurosurg. 2020 Jan;188:105566. doi: 10.1016/j.clineuro.2019.105566. PMID: 31731087.
Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS. "SEMA4C Is a Novel Target to Limit Osteosarcoma Growth, Progression, and Metastasis." Oncogene. 2020 Jan;39(5):1049-1062. doi: 10.1038/s41388-019-1041-x. PMID: 31582836.
Martin AM*, Bell WR*, Yuan M, Harris L, Poore B, Arnold A, Engle EL, Asnaghi L, Lim M, Raabe EH, Eberhart CG. "PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status." J Neuropathol Exp Neurol. 2020 Jan 1;79(1):74-85. doi: 10.1093/jnen/nlz119. PMID: 31819973. (*co-first author)
Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. "CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy." Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. PMID: 31624103.
Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. "Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma Is Independent of Base Excision Repair." Clin Cancer Res. 2020 Jan 3. doi: 10.1158/1078-0432.CCR-19-2000. Epub ahead of print. PMID: 31900275.
Koga T, Chaim IA, Benitez JA, Markmiller S, Parisian AD, Hevner RF, Turner KM, Hessenauer FM, D'Antonio M, Nguyen ND, Saberi S, Ma J, Miki S, Boyer AD, Ravits J, Frazer KA, Bafna V, Chen CC, Mischel PS, Yeo GW, Furnari FB. "Longitudinal Assessment of Tumor Development Using Cancer Avatars Derived from Genetically Engineered Pluripotent Stem Cells." Nat Commun. 2020 Jan 28;11(1):550. doi: 10.1038/s41467-020-14312-1. PMID: 31992716; PMCID: PMC6987220.
Ning J, Wakimoto H. "Therapeutic Application of PARP Inhibitors in Neuro-Oncology." Trends Cancer. 2020 Feb;6(2):147-159. doi: 10.1016/j.trecan.2019.12.004. PMID: 32061304.
Zhu Z, Mesci P, Bernatchez JA, Gimple RC, Wang X, Schafer ST, Wettersten HI, Beck S, Clark AE, Wu Q, Prager BC, Kim LJY, Dhanwani R, Sharma S, Garancher A, Weis SM, Mack SC, Negraes PD, Trujillo CA, Penalva LO, Feng J, Lan Z, Zhang R, Wessel AW, Dhawan S, Diamond MS, Chen CC, Wechsler-Reya RJ, Gage FH, Hu H, Siqueira-Neto JL, Muotri AR, Cheresh DA, Rich JN. "Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis." Cell Stem Cell. 2020 Feb 6;26(2):187-204.e10. doi: 10.1016/j.stem.2019.11.016. PMID: 31956038.
Beckmann PJ, Largaespada DA. "Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities." Int J Mol Sci. 2020 Feb 10;21(3):1172. doi: 10.3390/ijms21031172. PMID: 32050713; PMCID: PMC7036786.
Prahl LS, Stanslaski MR, Vargas P, Piel M, Odde DJ. "Predicting Confined 1D Cell Migration from Parameters Calibrated to a 2D Motor-Clutch Model." Biophys J. 2020 Feb 25:S0006-3495(20)30163-6. doi: 10.1016/j.bpj.2020.01.048. Epub ahead of print. PMID: 32145191.
Duckett MM, Phung SK, Nguyen L, Khammanivong A, Dickerson E, Dusenbery K, Lawrence J. "The Adrenergic Receptor Antagonists Propranolol and Carvedilol Decrease Bone Sarcoma Cell Viability and Sustained Carvedilol Reduces Clonogenic Survival and Increases Radiosensitivity in Canine Osteosarcoma Cells." Vet Comp Oncol. 2020 Mar;18(1):128-140. doi: 10.1111/vco.12560. PMID: 31778284.
Parikh BB, Neil EC. "Evolving Strategies to Potentially Further Optimize Surgical Interventions in Brain Cancer." Curr Oncol Rep. 2020 Mar 6;22(4):32. doi: 10.1007/s11912-020-0896-x. PMID: 32140793.
Borgatti A, Fieberg A, Winter AL, Stuebner K, Taras E, Todhunter D, Masyr A, Rendhal A, Vallera DA, Koopmeiners JS, Modiano JF. "Impact of Repeated Cycles of EGF Bispecific Angiotoxin (eBAT) Administered at a Reduced Interval from Doxorubicin Chemotherapy in Dogs with Splenic Hemangiosarcoma." Vet Comp Oncol. 2020 Mar 18. doi: 10.1111/vco.12590. Epub ahead of print. PMID: 32187827.
Rennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, Sloan AE, Kim AH, Leuthardt EC, Chen CC. "Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization." Neurosurgery. 2020 Apr 1;86(4):538-547. doi: 10.1093/neuros/nyz141. PMID: 31076762.
Williams LA, Moertel CL, Richardson M, Marcotte EL. "Incidence of Second Malignancies in Individuals Diagnosed with Malignant Peripheral Nerve Sheath Tumors." J Neurooncol. 2020 Apr 1. doi: 10.1007/s11060-020-03478-9. Epub ahead of print. PMID: 32239432.
Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, Rahrmann EP, Moriarity BS, Largaespada DA. "PLX3397 Treatment Inhibits Constitutive CSF1R-Induced Oncogenic ERK Signaling, Reduces Tumor Growth, and Metastatic Burden in Osteosarcoma." Bone. 2020 Apr 3:115353. doi: 10.1016/j.bone.2020.115353. Epub ahead of print. PMID: 32251854.
Ricard JA, Charles R, Yohe S, Bell WR, Flanagan ME. "Epstein Virus Barr Positive Diffuse Large B-cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis." Journal of Neuropathology and Experimental Neurology. Accepted 2019 Nov.
|
|
|
|
|
The Discovery Labs opened in Moos 2 this past winter, where 6 BTP professors now have their labs.
|
|
May 14 - BTP Data Club, Joseline Haizel-Cobbina, MD
June 11 - BTP Data Club, Renata Saha
July 9 - BTP Data Club, Florina Grigore
August 13 - BTP Data Club, TBD
|
|
|
|
Highlights & Recognitions
|
|
|
The Brain Tumor Program is excited to welcome five new members to our research team:
|
|
|
|
|
|
|
|
|
